Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adnan Derti

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Oncotarget|April 9, 2019
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced <i>NRAS</i>- or <i>BRAF</i>-mutated melanomaCarla M L van Herpen, Sanjiv S Agarwala, Axel Hauschild, et al.
Molecular Cancer Therapeutics|March 1, 2015
Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor EverolimusHung Huynh, Huai-Xiang Hao, Stephen L Chan, et al.
Molecular Cancer Therapeutics|February 8, 2020
Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071Sophie Piperno-Neumann, James Larkin, Richard D Carvajal, et al.
Nature|November 20, 2014
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitorDejan Juric, Pau Castel, Malachi Griffith, et al.
Nature Medicine|December 24, 2013
Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphomaRami Rahal, Mareike Frick, Rodrigo Romero, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Oncotarget|April 9, 2019
Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced <i>NRAS</i>- or <i>BRAF</i>-mutated melanomaCarla M L van Herpen, Sanjiv S Agarwala, Axel Hauschild, et al.
Molecular Cancer Therapeutics|March 1, 2015
Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor EverolimusHung Huynh, Huai-Xiang Hao, Stephen L Chan, et al.
Molecular Cancer Therapeutics|February 8, 2020
Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071Sophie Piperno-Neumann, James Larkin, Richard D Carvajal, et al.
Nature|November 20, 2014
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitorDejan Juric, Pau Castel, Malachi Griffith, et al.
Nature Medicine|December 24, 2013
Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphomaRami Rahal, Mareike Frick, Rodrigo Romero, et al.
Pageof 2